key: cord-1047563-j9921onu authors: Chen, Ming-Hsu; Chang, Po-Chun title: The Effectiveness of Mouthwash Against SARS-CoV-2 Infection: A Review of Scientific and Clinical Evidence date: 2021-10-08 journal: J Formos Med Assoc DOI: 10.1016/j.jfma.2021.10.001 sha: 9b2cabe81c5bf7048cf16d57a27b1dfffe674989 doc_id: 1047563 cord_uid: j9921onu Background/Purpose The COVID-19 pandemic, caused by the spread of SARS-CoV-2 infection that is mainly through the airborne transmission, is a worldwide health concern. This review seeks to assess the potential effectiveness of mouthwash in reducing the oropharyngeal load of SARS-CoV-2 based on the available evidence. Methods Articles related to mouthwash and COVID-19 in PubMed were electronically searched in July, 2021. After manually excluding articles lacking sufficient scientific evidence or validation processes, those with inaccessible online full text, those that did not test the effectiveness of mouthwash against SARS-CoV-2, and those not written in English, 17 original and 13 review articles were chosen for this review. Results The eligible articles revealed that the main virucidal mechanism of mouthwash was via interactions with the viral envelope. Povidone-iodine (PVP-I), cetylpyridinium chloride (CPC), and essential oils with ethanol showed virucidal effects on SARS-CoV-2 in vitro, potentially by interfering with the viral envelope. A few clinical studies demonstrated that PVP-I, CPC, hydrogen peroxide, and chlorhexidine reduced the oropharyngeal load of SARS-CoV-2. Conclusion Although the available evidence is limited, mouthwash containing PVP-I or CPC shows potential for reducing the oropharyngeal load of SARS-CoV-2 and thus may present a risk-mitigation strategy for COVID-19 patients. The COVID-19 pandemic, caused by the spread of a new coronavirus strain of SARS-CoV-2, has affected more than 200,000,000 individuals and caused more than 4,000,000 deaths worldwide in 2020-2021. 1 The primary routes of disease transmission were respiratory droplets and contact. 2 Clinical evidence showed that the virus was detectable in swabs of the upper respiratory tract and the self-collected saliva of patients infected by SARS-CoV-2. 3, 4 Angiotensin-converting enzyme 2 (ACE2), the main host cell receptor of SARS-CoV-2, was highly expressed by the oral mucosal epithelial cells. 5 Because the viral load of SARS-CoV-2 is associated with the severity of COVID-19, 6 reduction of the viral load in the oral cavity may reduce the severity of the disease. Antiviral mouthwash has been proposed as a low-cost and easily implemented strategy against SARS-CoV-2 infection, thereby reducing the risk of viral transmission. 7 This paper provides an evidence-based review to assist dental and healthcare professionals who are considering mouthwashes as an auxiliary strategy in controlling SARS-CoV-2 infection. It explains the potential mechanism by which mouthwashes may control SARS-CoV-2 infection and reviews in vitro and clinical research supporting the virucidal properties of mouthwashes on SARS-CoV-2. An electronic search of scientific articles in PubMed using the Boolean operators of "(mouthrinse OR mouthwash) AND (COVID OR SARS-CoV-2 OR coronavirus)" was performed on July 23, 2021. 122 articles were included in the subsequent screening, and the exclusion criteria were: The full text is inaccessible online. The article is a case report, case series, or clinical study with fewer than 5 participants per group, a letter to the editor, editorial, or short communication without an experimental section. The article is a summary of protocol or hypothesis without experimental validation. The article is a systematic review without any eligible articles for analysis. The tested compounds are not designed for oral use against SARS-CoV-2 infection.  None of the tested compounds revealed >90% inactivation of SARS-CoV-2 (for the in vitro studies only). The article is not written in English. After excluding the ineligible articles, a total of 30 articles were chosen. The characteristics of in vitro studies (9 articles) are listed in Table 1 , clinical studies (8 articles) in Table 2 , and 13 review articles (4 systematic reviews and 9 narrative reviews) in the Appendix. J o u r n a l P r e -p r o o f SARS-CoV-2 is covered with a lipid envelope that is embedded with spike glycoproteins, which interact with ACE2 to penetrate cells. 8 J o u r n a l P r e -p r o o f outbreaks, and that infectivity was further reduced to undetectable levels with 1 to 2 minutes' exposure. 16, 17 However, although the incidence was rare, adverse effects including contact dermatitis, allergies, and thyroid dysfunction, were reported when ≥1% PVP-I was utilized. 15, 18 Solutions of 4% and 5% PVP-I show toxicity to human keratinocytes and respiratory cells in vitro. 18 Six in vitro studies supported the virucidal effect of PVP-I-containing mouthwash against SARS-CoV-2 infection. Within 30-120 seconds of incubation with 5% PVP-I, >99.9% of SARS-CoV-2 was inactivated. 19 Pelletier et al. also demonstrated that a 60second incubation with 1-3% PVP-I inactivated >99.99% of SARS-CoV-2, equivalent to 70% ethanol under the same incubation conditions. 20 1% PVP-I 4 times daily for 5 days with supplemental PVP-I nasal spray but concluded that PVP-I did not significantly influence the change in viral load over 7 days compared with patients receiving a placebo treatment. 26 They also reported that thyroid dysfunction occurred in 42% of the patients receiving PVP-I treatment but spontaneously resolved after 7-12 days. Cetylpyridinium chloride (CPC) Quaternary ammonium compounds are widely used antimicrobial agents that interfere with the lipid components on the surface of bacteria, disrupt the integrity of the viral envelope, and are lysosomotropic, destroying the capsid of the virus. 12, 27, 28 Among these compounds, CPC is "generally regarded as safe" by the Food & Drug Administration and against severe coronaviruses with an effective dose (EC50) <5 M. 8 CPC is currently used in medicated mouthwashes at 0.02-0.075% concentration. 7, 12 Evidence as a mouthwash against SARS-CoV-2 infection properties and has been considered the gold standard of chemical plaque control. [31] [32] [33] Positively charged CHX reacts with negatively charged microbial surfaces, damaging the cytoplasmic membrane and causing leakage. 12 The virucidal mechanism has not been fully elucidated but is probably related to interaction with the viral envelope. 34 In general, the concentration of CHX in mouthwashes is 0.12-0.2% and the major adverse effects of CHX include tooth pigmentation, supragingival calculus deposition, and taste alteration. 31,32 The in vitro evidence of CHX against SARS-CoV-2 is controversial. Jain et al. HP targets the viral envelope by liberating oxygen free radicals and disrupting the lipid structure, 8 and a concentration of about 0.5% is virucidal to enveloped viruses, including coronavirus. 12 Concentrations of HP >5% may induce tissue damage, but 1-3% HP does not pose a significant risk of adverse effects and is generally accepted in mouthwash formulas. 31 Because SARS-CoV-2 is vulnerable to oxidation, 0.1% HP has been recommended as a preprocedural mouthwash to reduce the viral load. 32 The included in vitro evidence did not support the effectiveness of HP against Table 3 , although the available evidence is limited, a 30-second exposure to 0.5-1% PVP-I or 0.04-0.075% CPC appears to reduce the oropharyngeal load of SARS-CoV-2 and present a risk mitigation strategy for COVID-19 patients. The authors have no conflicts of interest relevant to this article. Community transmission of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 viral load in upper respiratory specimens of infected patients Consistent detection of 2019 novel coronavirus in saliva High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Viral dynamics in mild and severe cases of COVID-19 Oral antiseptics against coronavirus: in-vitro and clinical evidence Antiviral activity of reagents in mouth rinses against SARS-CoV-2 Role of the lipid rafts in the life cycle of canine coronavirus Virucidal activity of World Health Organization-recommended formulations against enveloped viruses, Including Zika, Ebola, and emerging coronaviruses Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection Review of the use of nasal and oral antiseptics during a global pandemic Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols Can povidone iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review Povidone-Iodine Solution: A potential antiseptic to minimize the risk of COVID-19? A narrative review Considerations for povidone-iodine antisepsis in pediatric nasal and pharyngeal surgery during the COVID-19 pandemic Lowering the transmission and spread of human coronavirus Efficacy of povidone-Iodine nasal and oral antiseptic preparations against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) Chlorhexidine: An effective anticovid mouth rinse In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes Virucidal efficacy of different oral rinses against severe acute respiratory syndrome coronavirus 2 Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore Povidone iodine mouthwash, gargle, and nasal spray to reduce nasopharyngeal viral load in patients with COVID-19: A randomized clinical trial Repurposing quaternary ammonium compounds as potential treatments for COVID-19 Mouthwashes with CPC reduce the infectivity of SARS-CoV-2 variants in vitro Virucidal activity of oral care products against SARS-CoV-2 in vitro Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols? COVID-19 and oral surgery: A narrative review of preoperative mouth rinses Antiviral mouthwashes: possible benefit for COVID-19 with evidence-based approach In vitro virucidal effectiveness of a 0.12%-chlorhexidine gluconate mouthrinse Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476 Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2 Effectiveness of hydrogen peroxide as auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of a randomized double-blind clinical trial The antiviral spectrum of Listerine antiseptic. Oral Surg Oral Med Oral Pathol Oral Radiol Endod Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial Corticosteroids in COVID-19 ARDS: Evidence and hope during the pandemic Mouthrinses against SARS-CoV-2: anti-inflammatory effectivity and a clinical pilot study The efficacy of bio-aerosol reducing procedures used in dentistry: a systematic review The publication of article was supported by the Cathay General Hospital and a research grant from the National Taiwan University (108L7853).J o u r n a l P r e -p r o o f